At the same time, the combination of circRNAs with epidermal growth factor receptor (EGFR) [19] or histone deacetylase (HDAC) inhibitors [20] has shown significant potential in restoring drug sensitivity in resistant glioma cells. This evidence concerns the gene HDAC9 and central nervous system cancer.